MA55504A - Anticorps dirigés contre le liraglutide et leur utilisation - Google Patents

Anticorps dirigés contre le liraglutide et leur utilisation

Info

Publication number
MA55504A
MA55504A MA055504A MA55504A MA55504A MA 55504 A MA55504 A MA 55504A MA 055504 A MA055504 A MA 055504A MA 55504 A MA55504 A MA 55504A MA 55504 A MA55504 A MA 55504A
Authority
MA
Morocco
Prior art keywords
liraglutide
antibodies against
antibodies
against liraglutide
Prior art date
Application number
MA055504A
Other languages
English (en)
Inventor
Arne Staby
Samuel D Stimple
Peter M Tessier
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA55504A publication Critical patent/MA55504A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
MA055504A 2019-04-01 2020-03-31 Anticorps dirigés contre le liraglutide et leur utilisation MA55504A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962827444P 2019-04-01 2019-04-01

Publications (1)

Publication Number Publication Date
MA55504A true MA55504A (fr) 2022-02-09

Family

ID=70154403

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055504A MA55504A (fr) 2019-04-01 2020-03-31 Anticorps dirigés contre le liraglutide et leur utilisation

Country Status (6)

Country Link
US (2) US11208477B2 (fr)
EP (1) EP3947451A1 (fr)
JP (2) JP7712210B2 (fr)
CN (2) CN120518763A (fr)
MA (1) MA55504A (fr)
WO (1) WO2020201280A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022140413A1 (fr) * 2020-12-22 2022-06-30 The Regents Of The University Of Michigan Anticorps spécifiques de l'amyloïde et utilisations associées
CN118440195B (zh) * 2022-06-17 2025-04-08 东莞市朋志生物科技有限公司 抗脂联素抗体、检测脂联素的试剂和试剂盒
CN116425858B (zh) * 2023-03-01 2024-04-19 浙江大学 一种荧光修饰的司美格鲁肽衍生物及其制备方法与应用
CN120399068A (zh) * 2025-04-29 2025-08-01 温州康瑞佰欧生物技术有限公司 基于电化学发光免疫分析的司美格鲁肽含量检测方法、检测司美格鲁肽的试剂盒以及单克隆抗体对

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620850A (en) 1994-09-26 1997-04-15 President And Fellows Of Harvard College Molecular recognition at surfaces derivatized with self-assembled monolayers
WO1996036883A1 (fr) 1995-05-17 1996-11-21 Novo Nordisk A/S Dosage immunologique dans le plasma de la proteine similaire au glucagon, de type 1 (glp-1)
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
EP0979102A4 (fr) 1997-04-30 2005-11-23 Enzon Inc Polypeptides a chaine unique modifies par oxyde de polyalkylene
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (fr) 2003-10-28 2005-05-06 Novo Nordisk A/S Peptides fixant la laminine-5 gamma-2, compositions associees et leurs applications
EP2298337B1 (fr) * 2003-12-09 2017-02-22 Novo Nordisk A/S Régulation des préférences alimentaires en utilisant des agonistes du GLP-1
WO2006036834A2 (fr) 2004-09-24 2006-04-06 Amgen Inc. Molecules fc modifiees
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1968645A4 (fr) 2005-12-22 2009-11-04 Centocor Ortho Biotech Inc Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations
JP2011523052A (ja) 2008-05-23 2011-08-04 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｌｐ−１受容体アゴニスト・バイオアッセイ
CA2755336C (fr) 2009-03-20 2015-07-14 Amgen Inc. Immunoglobulines porteuses et utilisations de celles-ci
AU2014250730B2 (en) * 2009-12-07 2016-10-13 Amgen Inc. Human antigen binding proteins that bind beta-Klotho, FGF receptors and complexes thereof
US20140221284A1 (en) 2011-01-21 2014-08-07 Ir2Dx, Inc. Biomarkers for Rapid Determination of Drug Efficacy
WO2014012082A2 (fr) 2012-07-13 2014-01-16 Zymeworks Inc. Conception d'échafaudages hétéromultimères et produits de recombinaison
WO2014056199A1 (fr) 2012-10-12 2014-04-17 清华大学 Procédés de production et de purification d'un polypeptide
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
EP3068891A1 (fr) 2013-11-13 2016-09-21 Aequus Biopharma Inc. Glycoprotéines modifiées et leurs utilisations
AR098615A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
CN103884846B (zh) 2014-03-06 2016-06-08 杭州九源基因工程有限公司 一种利拉鲁肽生物学活性的检测方法
GR20140100479A (el) * 2014-09-23 2016-05-05 Novetide, Ltd., Συνθεση λιραγλουτιδης
CN104267194B (zh) 2014-09-23 2016-01-13 上海市东方医院 人胰高血糖素样肽-1、抗体及其试剂盒
KR102665710B1 (ko) * 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도

Also Published As

Publication number Publication date
CN120518763A (zh) 2025-08-22
CN113677702A (zh) 2021-11-19
EP3947451A1 (fr) 2022-02-09
CN113677702B (zh) 2025-06-13
WO2020201280A1 (fr) 2020-10-08
US20200308274A1 (en) 2020-10-01
US12492249B2 (en) 2025-12-09
JP2022527812A (ja) 2022-06-06
US20220064283A1 (en) 2022-03-03
JP7712210B2 (ja) 2025-07-23
JP2025143464A (ja) 2025-10-01
US11208477B2 (en) 2021-12-28

Similar Documents

Publication Publication Date Title
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
MA52285A (fr) Anticorps multispécifiques et leur utilisation
EP3931561A4 (fr) Nanocapteurs et leur utilisation
EP3904386A4 (fr) Anticorps et son utilisation
EP3887403A4 (fr) Anticorps anti-4-1bb et son utilisation
EP4034094A4 (fr) Inhibiteurs de phosphodiestérase et leur utilisation
MA47311A (fr) Anticorps anti-tgf-bêta et leur utilisation
EP3907240A4 (fr) Anticorps anti-tnfr2 et son utilisation
EP3962956A4 (fr) Anticorps anti-hvem et leur utilisation
EP3802612A4 (fr) Anticorps anti-b7-h3 et son utilisation
EP3797124A4 (fr) Anticorps anti-ro1 et son utilisation
EP3740508A4 (fr) Anticorps et variants associés dirigés contre tigit
EP3442567A4 (fr) Anticorps anti-psma et leur utilisation
EP3448412A4 (fr) Anticorps anti-vista humain et leur utilisation
EP3728563A4 (fr) Cellules effectrices immunes améliorées et leur utilisation
EP4039705A4 (fr) Anticorps ciblant bcma, anticorps bispécifique et leur utilisation
EP3668972A4 (fr) Enzymes dnase génétiquement modifiées et leur utilisation en thérapie
EP3572427A4 (fr) Anticorps ciblant bcma et son utilisation
EP3875484A4 (fr) Anticorps ciblant cll1 et son utilisation
EP4001305A4 (fr) Anticorps anti-tau et son utilisation
EP3354661A4 (fr) Anticorps entièrement humain contre cd137 humain et son utilisation
EP3630844A4 (fr) Nouvel anticorps anti-c-met et son utilisation
EP3789486A4 (fr) Cellules effectrices immunitaires et leur utilisation
MA55504A (fr) Anticorps dirigés contre le liraglutide et leur utilisation
EP3733705A4 (fr) Anticorps monoclonaux et procédés de leur utilisation